In a study involving hemodialysis patients, ALA supplementation significantly reduced inflammation markers, a risk factor for cardiovascular disease. Researchers in Iran examined the effects of alpha-lipoic acid (ALA) supplementation on inflammation, oxidative stress, and serum lipid profile levels in HD patients. This double-blinded, randomized, placebo-controlled clinical trial included 63 patients with end-stage renal disease (43 men and 20 women; age range: 22-79 years) undergoing maintenance HD. Patients were randomly assigned into either the supplemented group (n = 31), receiving a daily dose of ALA (600 mg), or a control group (n = 32), receiving placebo for 8 weeks. Researchers looked at high sensitivity C-reactive protein (hsCRP), malondialdehyde, total antioxidant status, total cholesterol, triglyceride, high-density lipoprotein cholesterol (HDL-C), and low-density lipoprotein cholesterol (LDL-C) were measured at baseline and after 8 weeks of supplementation. Resu lts found that ALA supplementation was associated with a significant reduction in inflammatory markers, suggesting that ALA supplementation may reduce the risk of cardiovascular disease in hemodialysis patients.
Click here to visit the journal website. Subscription required to view the full text of the article.